Literature DB >> 16334707

Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia.

Andrew E Grulich1, Philip Cunningham, Mee-Ling Munier, Garrett Prestage, Janaki Amin, Clare Ringland, Denise Whitby, Susan Kippax, John M Kaldor, William Rawlinson.   

Abstract

BACKGROUND: Human herpesvirus 8 (HHV-8) is a common sexually transmitted agent among homosexual men, but there are few Australian data. We aimed to describe the prevalence and risk factors for seropositivity to HHV-8 in Australian homosexual men.
METHODS: We conducted a prospective cohort study of 179 homosexual men in Sydney Australia in 1992-1998. Detailed data on sexual behaviour was collected annually, and HHV-8 status was determined at the end of the study by an algorithm based on results of an immunofluorescence assay and an enzyme-linked immunoassay to the K8.1 protein of HHV-8. HHV-8 DNA was detected in buffy coats using a nested qualitative PCR.
RESULTS: Data on sexual behaviour in at least three interviews and HHV-8 status were available in 174 (97%) of 179 men who agreed to participate. Of these, 31 (18%) were HHV-8 seropositive, and HHV-8 DNA was detected in 5 (16%) of these. The prevalence of HHV-8 infection was much higher in HIV positive (52%) than HIV negative (11%) men (OR 8.60, 95% CI 3.55-20.86). HHV-8 infection was related to more frequent reporting of unprotected receptive anal sex (OR for most frequent versus least frequent category 3.03, 95% CI 1.01-9.03, P trend 0.02), insertive oro-anal sex (OR for most frequent v. least frequent category 3.02, 95% CI 1.15-7.93, P trend 0.02) and receptive oro-anal sex (OR for most frequent v. least frequent category 3.09, 95% CI 1.11-8.60, P trend 0.05) with casual partners.
CONCLUSIONS: These data are consistent with sexual transmission of HHV-8, but the precise mode of HHV-8 transmission remains unclear. Studies to elucidate the precise mode of sexual transmission of HHV-8 need to focus on potential salivary transmission, and should collect data on the HHV-8 infection and excretion status of the sexual partner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16334707     DOI: 10.1071/sh04029

Source DB:  PubMed          Journal:  Sex Health        ISSN: 1448-5028            Impact factor:   2.706


  6 in total

1.  Seroprevalence and determinants of Kaposi sarcoma-associated human herpesvirus 8 in Indian HIV-infected males.

Authors:  Arshi Munawwar; Surendra K Sharma; Somesh Gupta; Sarman Singh
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

Review 2.  HIV-associated Kaposi sarcoma and related diseases.

Authors:  Priscila H Gonçalves; Thomas S Uldrick; Robert Yarchoan
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

3.  Prevalence and correlates of human herpesvirus 8 infection among Peruvian men who have sex with men.

Authors:  Juan V Guanira; Corey Casper; Javier R Lama; Rhoda Morrow; Silvia M Montano; Patricia Caballero; Luis Suárez; William L H Whittington; Anna Wald; Jorge Sanchez; Connie Celum
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

4.  Pathology of Kaposi's Sarcoma-Associated Herpesvirus Infection.

Authors:  Hitomi Fukumoto; Takayuki Kanno; Hideki Hasegawa; Harutaka Katano
Journal:  Front Microbiol       Date:  2011-08-25       Impact factor: 5.640

Review 5.  KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine.

Authors:  Corey Casper; Lawrence Corey; Jeffrey I Cohen; Blossom Damania; Anne A Gershon; David C Kaslow; Laurie T Krug; Jeffrey Martin; Sam M Mbulaiteye; Edward S Mocarski; Patrick S Moore; Javier Gordon Ogembo; Warren Phipps; Denise Whitby; Charles Wood
Journal:  NPJ Vaccines       Date:  2022-09-20       Impact factor: 9.399

6.  Detection of human herpesvirus 8 by quantitative polymerase chain reaction: development and standardisation of methods.

Authors:  David J Speicher; Newell W Johnson
Journal:  BMC Infect Dis       Date:  2012-09-11       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.